What the research found

Researchers created a comprehensive map of microproteins—proteins smaller than 100–150 amino acids—in aged human brain tissue. These proteins have been systematically missed by standard proteomics databases and research, largely because detection methods have historically focused on larger molecules. The study identified over 1,000 microproteins that are actually present and functional in the aging brain.

One microprotein of particular interest comes from the MKKS gene. This protein appears to be involved in energy metabolism within microglia (the brain's immune cells). In Alzheimer's disease brain samples, levels of this microprotein were notably lower than in healthy aging brains, suggesting a potential link between its depletion and neurodegeneration.

Why it matters for you

If you're tracking biomarkers or optimizing cognitive function as you age, this work highlights a blind spot in how we've understood brain aging. Most blood biomarkers and CSF panels don't yet capture microprotein signatures—they're too new to the field. But this atlas now provides a foundation for developing targeted measurements, which could eventually become part of comprehensive neurodegeneration risk assessment.

The energy metabolism angle is particularly relevant if you're using interventions (supplements, peptides, or training protocols) aimed at supporting mitochondrial function or microglial health. Currently there's no practical way to measure MKKS microprotein or similar molecules in living humans, but as assays develop, these could become markers worth monitoring—especially if family history or cognitive concerns make neurological aging a priority for you.

Caveats

  • Post-mortem tissue only: findings come from brain samples after death; we don't yet know how these microproteins behave in the living brain
  • No clinical intervention data: this is a mapping study, not a trial; we don't know if targeting or restoring these microproteins would slow decline
  • Early-stage biomarker work: the MKKS finding is correlational; causality is not established
  • No human blood or fluid biomarkers yet: these microproteins cannot currently be measured outside the brain in accessible samples